Literature DB >> 24732941

Melanoma: Why is sentinel lymph node biopsy 'standard of care' for melanoma?

James C Yang1, Richard M Sherry1, Steven A Rosenberg1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24732941      PMCID： PMC6453120          DOI： 10.1038/nrclinonc.2014.65

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Inefficacy of immediate node dissection in stage 1 melanoma of the limbs.

Authors:  U Veronesi; J Adamus; D C Bandiera; I O Brennhovd; E Caceres; N Cascinelli; F Claudio; R L Ikonopisov; V V Javorskj; S Kirov; A Kulakowski; J Lacoub; F Lejeune; Z Mechl; A Morabito; I Rodé; S Sergeev; E van Slooten; K Szcygiel; N N Trapeznikov
Journal:  N Engl J Med       Date:  1977-09-22       Impact factor: 91.245

Review 2.  Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review.

Authors:  Z V Fong; K K Tanabe
Journal:  Br J Dermatol       Date:  2014-01       Impact factor: 9.302

3.  Technical details of intraoperative lymphatic mapping for early stage melanoma.

Authors:  D L Morton; D R Wen; J H Wong; J S Economou; L A Cagle; F K Storm; L J Foshag; A J Cochran
Journal:  Arch Surg       Date:  1992-04

4.  Sentinel-node biopsy or nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

5.  Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial.

Authors:  C M Balch; S Soong; M I Ross; M M Urist; C P Karakousis; W J Temple; M C Mihm; R L Barnhill; W R Jewell; H J Wanebo; R Harrison
Journal:  Ann Surg Oncol       Date:  2000-03       Impact factor: 5.344

6.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

7.  A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.

Authors:  John M Kirkwood; Judith Manola; Joseph Ibrahim; Vernon Sondak; Marc S Ernstoff; Uma Rao
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531

8.  Cost-effectiveness of sentinel lymph node biopsy in thin melanomas.

Authors:  Doreen M Agnese; Shahab F Abdessalam; William E Burak; Cynthia M Magro; Rodney V Pozderac; Michael J Walker
Journal:  Surgery       Date:  2003-10       Impact factor: 3.982

9.  Revised U.K. guidelines for the management of cutaneous melanoma 2010.

Authors:  J R Marsden; J A Newton-Bishop; L Burrows; M Cook; P G Corrie; N H Cox; M E Gore; P Lorigan; R MacKie; P Nathan; H Peach; B Powell; C Walker
Journal:  Br J Dermatol       Date:  2010-07-01       Impact factor: 9.302
  9 in total
  5 in total

Review 1.  A review of sentinel lymph node biopsy for thin melanoma.

Authors:  K M Joyce; N M McInerney; C W Joyce; D M Jones; A J Hussey; P Donnellan; M J Kerin; J L Kelly; P J Regan
Journal:  Ir J Med Sci       Date:  2014-11-01       Impact factor: 1.568

2.  Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.

Authors:  J Yan; C Tingey; R Lyde; T C Gorham; D K Choo; A Muthumani; D Myles; L P Weiner; K A Kraynyak; E L Reuschel; T H Finkel; J J Kim; N Y Sardesai; K E Ugen; K Muthumani; D B Weiner
Journal:  Cancer Gene Ther       Date:  2014-11-14       Impact factor: 5.987

3.  MSLT-I-response of clinical trial investigators.

Authors:  James C Yang; Richard M Sherry
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

4.  MSLT-I-response of clinical trial investigators.

Authors:  Mark B Faries; Alistair J Cochran; John F Thompson
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

Review 5.  Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.

Authors:  Athanassios Kyrgidis; Thrasivoulos Tzellos; Simone Mocellin; Zoe Apalla; Aimilios Lallas; Pierluigi Pilati; Alexander Stratigos
Journal:  Cochrane Database Syst Rev       Date:  2015-05-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.